Verrica Pharmaceuticals Inc.
VRCA · XNASCIK 1660334fmd_1GAD2PBAXHJNF09TFH7FWMM404Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 39 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 12 | 9 | 5 | 8 | 36 |
| Cost of revenue | – | – | – | – | – | – | 1 | 3 | – |
| Gross profit | – | – | – | – | – | – | 5 | 5 | – |
| Research and development | 4 | 13 | 15 | 16 | 16 | 12 | 20 | 12 | 9 |
| Selling, general and administrative | – | – | – | – | – | 17 | 47 | 59 | 35 |
| Total operating expenses | 4 | 22 | 30 | 40 | 43 | 30 | 71 | 73 | 48 |
| Operating income | (4) | (22) | (30) | (40) | (31) | (21) | (66) | (66) | (12) |
| Interest expense | – | – | – | 3 | 4 | 2 | 4 | 9 | 8 |
| Interest and investment income | – | 1 | 2 | 1 | 0 | 0 | 3 | 1 | 1 |
| Other non-operating income (expense) | (0) | 1 | 2 | (3) | (4) | (3) | (1) | (11) | (6) |
| Income tax expense | – | – | – | – | – | 0 | 0 | 0 | 0 |
| Net income | (4) | (21) | (28) | (43) | (35) | (24) | (67) | (77) | (18) |
| Net income to common shareholders | (10) | (21) | – | – | – | – | – | – | – |